Pfizer Hosts Annual Meeting of Shareholders
April 25 2019 - 11:17AM
Business Wire
Declares 36-Cent Second-Quarter 2019
Dividend
The board of directors of Pfizer Inc. today declared a 36-cent
second-quarter 2019 dividend on the company’s common stock, payable
June 7, 2019 to shareholders of record at the close of business on
May 10, 2019. The second-quarter 2019 cash dividend will be the
322nd consecutive quarterly dividend paid by Pfizer.
“In 2018, we estimate that we reached more than 784 million
people with our products,” stated Albert Bourla, Pfizer Chief
Executive Officer. “Our vaccines protected more than 65 million
babies and elderly patients from disease; more than 48 million
cardiovascular patients took our medicines to reduce their risk of
heart attack or stroke; and more than 1.2 million people were
treated with our cancer treatments. Our unwavering focus on patient
impact by discovering breakthroughs that change patients’
lives will continue to be fundamental to our growth strategy
for the future.”
He continued, “Our ability to have a demonstrable impact on
patients drives our financial performance and creates shareholder
value. In 2018, we returned $20.2 billion to shareholders through
dividends and share repurchases. We will continue to pursue
initiatives in 2019 that create the most value for our shareholders
by serving our patients with advancements in scientific innovation,
our late-stage pipeline and our commercial therapies.”
Preliminary results from the Annual Meeting of Shareholders held
today indicate that the company’s 11 director nominees were
re-elected to one-year terms and that shareholders
ratified the selection of KPMG LLP as Pfizer’s independent
registered public accounting firm for the 2019 fiscal year. In
addition, shareholders supported the board-sponsored proposals to
approve, on an advisory basis, the compensation of the company’s
named executive officers and approved the Pfizer Inc. 2019 Stock
Plan which will replace and supersede the 2014 Stock Plan and
support the company’s efforts to attract, retain and motivate
employees.
In other voting, the shareholder proposals were not
approved.
The final results are subject to verification by the independent
inspectors of election. The final results will be reported on a
Current Report on Form 8-K to be filed by Pfizer with the U.S.
Securities and Exchange Commission in the next few days.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, we have worked to make a difference for
all who rely on us. We routinely post information that may be
important to investors on our website at www.pfizer.com. In
addition, to learn more, please visit us
on www.pfizer.com and follow us on Twitter
at @Pfizer and @Pfizer_News, LinkedIn, YouTube,
and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is
as of April 25, 2019. The Company assumes no obligation to update
forward-looking statements contained in this release as a result of
new information or future events or developments.
This release contains forward-looking information about the
Company’s growth strategy and actions to enhance shareholder value,
including their potential benefits, that involves substantial risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, the
uncertainties inherent in research and development; the
uncertainties inherent in business and financial planning,
including, without limitation, risks related to Pfizer’s business
and prospects, adverse developments in Pfizer’s markets, or
adverse developments in the U.S. or global capital markets,
credit markets, regulatory environment or economies generally;
and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2018 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results,” as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190425005635/en/
Media:Patricia Kelly(212) 733-3810
Investor:Ryan Crowe(212) 733-8160
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024